Sign In
Buy GRFS
$7.18
-0.100 (-1.37%)
At Close: Jun 23, 2026
Grifols: Valuation Discount Remains Wide Despite An Upbeat Capital Markets Day
11:49am, Friday, 02'nd Jul 2021
Grifols outlines some promising new initiatives and financial targets at its latest Capital Markets Day. The most notable shift this time around was the R&D/innovation focus, which should boost the lo
Singapore's sovereign fund invests $1 billion in Grifols's U.S. unit
04:10am, Wednesday, 30'th Jun 2021
Singapore's wealth fund GIC agreed to invest around 1 billion dollars in Biomat, a U.S.-based plasma collection company owned by Grifols, thus becoming a strategic investor in the Spanish pharmaceutic
BARCELONA, Spain, April 28, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contribu
5 Profitable Stocks With a Margin of Safety
11:33am, Wednesday, 21'st Apr 2021
According to the GuruFocus discounted cash flow calculator as of April 21, the following companies have a high margin of safety and have grown their margins over a 10-year period.
Grifols: The Plasma-Supply Disruption Provides An Attractive Entry Point
03:43pm, Tuesday, 20'th Apr 2021
Grifols operates in the very attractive and lucrative plasma business.
Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021
10:30am, Friday, 09'th Apr 2021
BARCELONA, Spain, April 9, 2021 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United S
BARCELONA, Spain, April 2, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years
BARCELONA, Spain, March 9, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the h
Moving Average Crossover Alert: Grifols
08:21am, Monday, 08'th Mar 2021
Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Is Grifols (GRFS) a Great Value Stock Right Now?
12:51pm, Thursday, 04'th Feb 2021
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
GRFS vs. ZTS: Which Stock Is the Better Value Option?
12:52pm, Wednesday, 03'rd Feb 2021
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19
06:00am, Monday, 18'th Jan 2021
BARCELONA, Spain, Jan. 18, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more t
GRFS or ZTS: Which Is the Better Value Stock Right Now?
12:48pm, Tuesday, 12'th Jan 2021
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Portfolio Manager Diary: Contrast The Information Obtained By The Company Management Before Investing
02:07pm, Sunday, 03'rd Jan 2021
Good prospects for the global immunoglobulin business. Koru Medical's strategic plan is to reach $ 50M in sales by 2022, a gross margin of 70%, and organic and annual sales growth of + 20%.
The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies
09:14am, Monday, 16'th Nov 2020
BARCELONA, Spain, Nov. 16, 2020 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with mo
